[Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
Hausmann
Ralph
R
Thalmann
George
G
Reich
Oliver
O
Steif
Christian G
CG
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D018450:Disease Progression; D004311:Double-Blind Method; D017292:Doxazosin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D018120:Finasteride / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010919:Placebos; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D011471:Prostatic Neoplasms / Q000517:prevention & control; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D010919:Placebos; D018120:Finasteride; D017430:Prostate-Specific Antigen; D017292:Doxazosin
Therapie der BPH mit Finasterid und Doxazosin--Langzeitbeobachtung spricht für Kombination.